Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients-Reference-Cited by-同舟云学术

Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients

Published:2019-01-01 Issue: Volume:18 Page:232595821882165
ISSN:2325-9582
Container-title:Journal of the International Association of Providers of AIDS Care (JIAPAC)
language:en
Short-container-title:J Int Assoc Provid AIDS Care

Author:

Riccardi Niccolò¹^ORCID,Del Puente Filippo¹,Taramasso Lucia¹^ORCID,Di Biagio Antonio²

Affiliation:

1. Infectious Diseases, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy

2. Infectious Diseases, Policlinico San Martino Hospital, Genoa, Italy

Abstract

Non-nucleoside reverse-transcriptase inhibitor plus integrase strand transfer inhibitor–based dual therapies are an attractive simplification, nucleoside reverse transcriptase inhibitor-sparing strategy for experienced human immunodeficiency virus-infected patients. Thus, we performed a 24-week real-life observational study to assess efficacy and safety of switching from raltegravir plus etravirine to dolutegravir plus rilpivirine in 7 previously heavily treated patients. This simplification strategy reduced pill burden and preserved viral suppression in treatment-experienced patients with no major mutations to rilpivirine at historical genotyping.

Publisher

SAGE Publications

Subject

Infectious Diseases,Dermatology,Immunology

Link

http://journals.sagepub.com/doi/pdf/10.1177/2325958218821657

Reference16 articles.

1. Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study

2. The Use of Nucleoside Reverse Transcriptase Inhibitors Sparing Regimens in Treatment-Experienced HIV-1 Infected Patients

3. A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data

4. Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort

5. Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature;Expert Review of Anti-infective Therapy;2022-11-27

2. Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV;Pharmaceuticals;2020-06-11

3. Response to letter to the editor;AIDS;2019-11-15

4. Simplifying ARV Therapy in the Setting of Resistance;Current Infectious Disease Reports;2019-09-07